AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Horizon Therapeutics plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2019

DUBLIN--(BUSINESS WIRE)--May 6, 2019--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees.

The restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee’s continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company’s 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.

The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

About Horizon Therapeutics plc

Horizon Therapeutics plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190506005214/en/

CONTACT: Tina Ventura

Senior Vice President, Investor Relations

Investor-relations@horizontherapeutics.comRuth Venning

Executive Director, Investor Relations

Investor-relations@horizontherapeutics.comU.S. Media Contact:

Geoffrey Curtis

Executive Vice President, Corporate Affairs & Chief Communications Officer

media@horizontherapeutics.comIreland Media Contact:

Ray Gordon

Gordon MRM

ray@gordonmrm.ie

KEYWORD: UNITED STATES EUROPE NORTH AMERICA NEW YORK IRELAND

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Horizon Therapeutics plc

Copyright Business Wire 2019.

PUB: 05/06/2019 08:00 AM/DISC: 05/06/2019 08:01 AM

http://www.businesswire.com/news/home/20190506005214/en